Dong-A ST Co., Ltd.

A170900

KR7170900005

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
67,500 ^KRW	-2.17%		-2.32%	-2.32%

Mar. 18	Dong-A ST Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 24	GenEdit Inc. announced that it has received $24 million in funding from Korea Innovative Medicines Consortium, Dong-A ST Co., Ltd., Huons Co., Ltd.	CI

Tranche Update on Dong-A ST Co., Ltd.'s Equity Buyback Plan announced on January 26, 2023.

April 26, 2023 at 12:13 am EDT

From January 26, 2023 to March 31, 2023, the company has repurchased 30,806 shares, representing 0.36% for KRW 1,853.28 million. With this, the company has completed the repurchase of 30,806 shares, representing 0.36% for KRW 1,853.28 million under the buyback announced on January 26, 2023.

Latest news about Dong-A ST Co., Ltd.

Dong-A ST Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
GenEdit Inc. announced that it has received $24 million in funding from Korea Innovative Medicines Consortium, Dong-A ST Co., Ltd., Huons Co., Ltd.	Jan. 23	CI
FDA Accepts for Review BLA for DMB-3115 of Dong-A ST, a Proposed Biosimilar to Stelara	Jan. 05	CI
Dong-A ST Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
MEZOO Co.,Ltd. announced that it has received KRW 18 billion in funding from a group of investors	Nov. 06	CI
Tranche Update on Dong-A ST Co., Ltd.'s Equity Buyback Plan announced on July 26, 2023.	23-10-19	CI
Tranche Update on Dong-A ST Co., Ltd.'s Equity Buyback Plan announced on July 26, 2023.	23-10-19	CI
Dong-A ST Co., Ltd.'s Equity Buyback announced on July 26, 2023, has closed with 38,373 shares, representing 0.45% for KRW 2,296.31 million.	23-10-16	CI
Dong-A ST Sets Sight on European Market with Stelara Biosimilar Expansion	23-08-31	MT
Dong-A ST Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Dong-A ST Co., Ltd. announces an Equity Buyback for 38,373 shares.	23-07-26	CI
Tranche Update on Dong-A ST Co., Ltd.'s Equity Buyback Plan announced on April 26, 2023.	23-07-25	CI
Tranche Update on Dong-A ST Co., Ltd.'s Equity Buyback Plan announced on April 26, 2023.	23-07-25	CI
Dong-A ST Co., Ltd. authorizes a Buyback Plan.	23-07-25	CI
EMA Accepts MAA for DMB-3115 of Dong-A ST, a Stelara Biosimilar	23-07-17	CI
Dong-A ST Co., Ltd.'s Equity Buyback announced on April 26, 2023, has closed with 45,872 shares, representing 0.54% for KRW 2,520.87 million.	23-07-16	CI
Dong-A ST Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Dong-A ST Co., Ltd. announces an Equity Buyback for 45,872 shares.	23-04-26	CI
Tranche Update on Dong-A ST Co., Ltd.'s Equity Buyback Plan announced on January 26, 2023.	23-04-26	CI
Tranche Update on Dong-A ST Co., Ltd.'s Equity Buyback Plan announced on January 26, 2023.	23-04-26	CI
Dong-A ST Co., Ltd. authorizes a Buyback Plan.	23-04-25	CI
Dong-A ST Co., Ltd.'s Equity Buyback announced on January 26, 2023, has closed with 40,519 shares, representing 0.47% for KRW 2,405.93 million	23-04-24	CI
GenEdit Inc. amended terms of the transaction	23-02-27	CI
Dong-A ST Co., Ltd. announces an Equity Buyback for 40,519 shares.	23-01-25	CI
Dong-A ST Co., Ltd. authorizes a Buyback Plan.	23-01-25	CI

Chart Dong-A ST Co., Ltd.

Duration

Period

More charts

Company Profile

Dong-A ST Co Ltd is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The Company is involved of the manufacturing and sale of gastric mucosal protective agents, antihistamines, ischemic modifiers, antithrombotic agents, functional dyspepsia, hyperlipidemia, growth hormone, peptic ulcer treatments, cerebral metabolism improvement and hypertension treatments. It produces and sells diagnostic reagents for hepatitis E, I, A and B. In addition, it is engaged in the production and sale of medical devices including implants for artificial joint and maxillofacial surgery. The Company distributes its products in domestic and overseas markets such as Brazil, Turkey and Cambodia.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Dong-A ST Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
DONG-A ST CO., LTD.	-2.32%	427M
MERCK KGAA	+5.31%	70.44B
KYOWA KIRIN CO. LTD.	+10.97%	8.94B
SK BIOPHARMACEUTICALS CO., LTD.	-16.83%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43.48%	4.5B
YUHAN CORPORATION	+3.20%	3.85B
INDIVIOR PLC	+18.82%	2.38B
BETTA PHARMACEUTICALS CO., LTD.	-21.36%	2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.67%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.38%	1.96B

Specialty & Advanced Pharmaceuticals

Dong-A ST Co., Ltd.

Equities

A170900

KR7170900005

Pharmaceuticals

Tranche Update on Dong-A ST Co., Ltd.'s Equity Buyback Plan announced on January 26, 2023.

Latest news about Dong-A ST Co., Ltd.

Chart Dong-A ST Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Dong-A ST Co., Ltd.

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals